UNCY – unicycive therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 [Yahoo! Finance]
Form EFFECT Unicycive Therapeutics,
Form EFFECT Unicycive Therapeutics,
Form SC 13G/A Unicycive Therapeutics, Filed by: Logos Global Management LP
Form SC 13G/A Unicycive Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.
Form SC 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.